Literature DB >> 19270532

Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells.

Feng Zhang1, Tao Zhang, Zeng-Hui Teng, Rong Zhang, Jian-Bo Wang, Qi-Bing Mei.   

Abstract

Histone deacetylase (HDAC) inhibitors (HDIs) play an important role in the regulation of gene expression associated with cell cycle and apoptosis and have emerged as promising anticancer agents. In addition to their intrinsic anticancer properties, some studies have demonstrated that HDIs can modulate cellular responses to ionizing radiation (IR). Here we show evidence that co-treatment with the HDI trichostatin A (TSA) radiosensitizes human non-small cell lung cancer (NSCLC) A549 cells and H1650 cells. Cells were exposed to gamma-irradiation with or without TSA co-treatment. Clonogenic survival was significantly reduced in cells with TSA co-treatment. In A549 cells, TSA enhanced IR-induced accumulation of cells in G(2)/M phase, with upregulated expression of p21(waf1/cip1). In addition, TSA co-treatment caused pronounced apoptosis in irradiated cells, which was accompanied with p21(waf1/cip1) cleavage to a 15 kDa protein. The enhanced apoptotic effect was via mitochondrial pathway, as indicated by the increased dissipation of mitochondrial transmembrane potential (MMP) and release of cytochrome c from the mitochondria to the cytoplasm. Caspase-3 activation was also significantly increased, with accordingly more cleavage of PARP, associated with the repression of X-linked inhibitor of apoptosis protein (XIAP). Furthermore, TSA co-treatment impaired DNA repair capacity after IR by downregulation of Ku70, Ku80 and DNA-PKcs, reflected by enhanced and prolonged expression of gammaH2AX. Taken together, our results demonstrate that TSA acts as a powerful radiosensitizer in NSCLC cells by enhancing G(2)/M cell cycle arrest, promoting apoptosis through multiple pathways and interfering with DNA damage repair processes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19270532     DOI: 10.4161/cbt.8.9.8143

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  36 in total

1.  Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.

Authors:  Nilsa Rivera-Del Valle; Tiewei Cheng; Mary E Irwin; Hayley Donnella; Melissa M Singh; Joya Chandra
Journal:  Cancer Chemother Pharmacol       Date:  2018-01-08       Impact factor: 3.333

Review 2.  Pharmacological methods to transcriptionally modulate double-strand break DNA repair.

Authors:  Alanna R Kaplan; Peter M Glazer
Journal:  Int Rev Cell Mol Biol       Date:  2019-12-18       Impact factor: 6.813

3.  Contribution of decreased expression of Ku70 to enhanced radiosensitivity by sodium butyrate in glioblastoma cell line (U251).

Authors:  Yuhui Li; Hongxia Zhou; Enming Xing; Meera Dassarath; Jinghua Ren; Xiaorong Dong; Hongli Liu; Kunyu Yang; Gang Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

4.  Valproic acid causes radiosensitivity of breast cancer cells via disrupting the DNA repair pathway.

Authors:  Yue Luo; Hui Wang; Xipeng Zhao; Chao Dong; Fengmei Zhang; Gang Guo; Gongshe Guo; Xiaowei Wang; Simon N Powell; Zhihui Feng
Journal:  Toxicol Res (Camb)       Date:  2016-02-18       Impact factor: 3.524

Review 5.  Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives.

Authors:  Insa Schiffmann; Gabriele Greve; Manfred Jung; Michael Lübbert
Journal:  Epigenetics       Date:  2016-11-15       Impact factor: 4.528

Review 6.  HDAC inhibitor-based therapies: can we interpret the code?

Authors:  Maria New; Heidi Olzscha; Nicholas B La Thangue
Journal:  Mol Oncol       Date:  2012-10-23       Impact factor: 6.603

Review 7.  HLA-G regulators in cancer medicine: an outline of key requirements.

Authors:  Ines Zidi; Nidhal Ben Amor
Journal:  Tumour Biol       Date:  2011-07-27

8.  New paradigms and future challenges in radiation oncology: an update of biological targets and technology.

Authors:  Stanley L Liauw; Philip P Connell; Ralph R Weichselbaum
Journal:  Sci Transl Med       Date:  2013-02-20       Impact factor: 17.956

9.  Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.

Authors:  Carine Robert; Pratik K Nagaria; Nisha Pawar; Adeoluwa Adewuyi; Ivana Gojo; David J Meyers; Philip A Cole; Feyruz V Rassool
Journal:  Leuk Res       Date:  2016-03-30       Impact factor: 3.156

Review 10.  Epigenetics in non-small cell lung cancer: from basics to therapeutics.

Authors:  Junaid Ansari; Rodney E Shackelford; Hazem El-Osta
Journal:  Transl Lung Cancer Res       Date:  2016-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.